Related Experiment Video

Updated: Dec 19, 2025

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.6K

Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy

Weijia Han1,2, Huanqian Zhang3, Ying Han4

  • 1Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.

Metabolic Brain Disease
|June 5, 2020
PubMed

Insights

Minimal hepatic encephalopathy (MHE) causes mild cognitive impairment in cirrhosis patients. This review covers MHE

Area of Science:

  • Neuroscience
  • Hepatology
  • Cognitive Science

Background:

  • Minimal hepatic encephalopathy (MHE) is a subtle cirrhosis complication impacting daily life.
  • MHE often goes undiagnosed and untreated due to insufficient guideline attention.
  • Cognitive impairment in MHE affects patient functioning and quality of life.

Purpose of the Study:

  • To review recent research on MHE-related cognitive impairment.
  • To provide updated information on MHE diagnosis and treatment.

Main Methods:

  • Literature review of cognition-based research.
  • Focus on cellular alterations, diagnostic methods, and therapeutic approaches for MHE.

Main Results:

  • Research indicates alterations in astrocytes, microglial cells, and neurons in MHE.
  • Various methods exist for detecting cognitive impairment in MHE.
  • Different therapeutic strategies are available for MHE cognitive impairment.

Conclusions:

  • Updated knowledge on MHE diagnosis and treatment is crucial.
  • Further research and guideline development are needed for MHE patients.
Keywords:
Cognitive impairmentDiagnosis and treatmentMinimal hepatic encephalopathyNerve cells

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.5K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.3K

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
438
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
675
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
117
Amnesia01:13

Amnesia

Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
346